Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in ...

The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British ...

To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it ...

While the possibility of levies on branded pharmaceuticals have had a limited impact on drugmaker revenues, tariffs of up to ...

The startup has a broad global development program underway — and the support of more than 20 investment firms — for a ...

The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s ...

The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are ...

The young venture firm, which has bet heavily on tech and biotech’s convergence, has now invested in 35 companies and ...

A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a ...

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s ...

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, ...